Aaron T. Gerds, MD, MS / John Mascarenhas, MD – Shaping Modern Management of Myelofibrosis: Guidance on the Conjunction of Targeted Therapy and AlloHCT

Go online to PeerView.com/SDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to develop personalized treatment plans for your patients with myelofibrosis (MF) that incorporate the latest therapeutic options, including JAK inhibitors, targeted strategies, and HCT? Find out in this new PeerView CME activity, featuring two experts who will use case-based clinical discussions to illustrate how they manage MF with the individual patient in mind. They will use these cases to discuss eligibility for HCT and the need for pre-HCT therapy based on disease risk factors; use of JAK inhibitor in non-HCT settings; practical dosing and safety management considerations; and the emergence of novel targeted and combinatorial strategies in the MF setting. Watch this informative update on personalized care for patients with MF! Upon completion of this activity, participants should be better able to: Discuss patient- and disease-related features of MF that inform prognosis and guide the selection of JAK inhibitors, other targeted strategies, and HCT; Summarize efficacy and safety data surrounding the use of JAK inhibitors, novel targeted strategies, and innovative combination regimens in MF across the therapeutic continuum; and Develop treatment plans that incorporate JAK inhibitors and other novel therapies to manage MF in HCT and non-HCT settings